表紙
市場調査レポート

尋常性乾癬:世界の治験レビュー

Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H2, 2014

発行 GlobalData 商品コード 318823
出版日 ページ情報 英文 132 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
尋常性乾癬:世界の治験レビュー Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H2, 2014
出版日: 2014年10月31日 ページ情報: 英文 132 Pages
概要

当レポートでは、尋常性乾癬の臨床試験に関連する基本情報やデータを提供しており、試験件数および被験者の募集状況、段階別の動向、臨床試験を実施している主な製薬企業および研究機関のプロファイルなどを提供しています。

イントロダクション

  • 尋常性乾癬
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要5カ国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:免疫疾患治療薬の治験における尋常性乾癬の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:免疫疾患治療薬の治験における尋常性乾癬の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

尋常性乾癬治療薬の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース 尋常性乾癬

治験のプロファイル

  • 主要企業の治験の概要
    • The LEO Foundation
    • Johnson & Johnson
    • Amgen Inc.
    • Pfizer Inc.
    • AbbVie Inc.
    • マルホ
    • Novartis AG
    • Galderma S.A.
    • Merck & Co., Inc.
    • アステラス製薬
  • 代表的な研究機関・病院の治験の概要
    • Guangdong Provincial Hospital of Traditional Chinese Medicine
    • University of California, San Francisco
    • Mount Sinai Hospital
    • Medical University of Vienna
    • Rockefeller University
    • Dresden University of Technology
    • Tehran University of Medical Sciences
    • Peking University People's Hospital
    • Chang Gung Memorial Foundation
    • Postgraduate Institute of Medical Education and Research

5つの代表的な治験のプロファイル

付録

目次
Product Code: GDHC2404CTIDB

GlobalData's clinical trial report, "Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H2, 2014" provides data on the Plaque Psoriasis (Psoriasis Vulgaris) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Plaque Psoriasis (Psoriasis Vulgaris). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Plaque Psoriasis (Psoriasis Vulgaris). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Plaque Psoriasis (Psoriasis Vulgaris)
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Plaque Psoriasis (Psoriasis Vulgaris)
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Plaque Psoriasis (Psoriasis Vulgaris)
    • Oct 16, 2014: New Analyses of Oral OTEZLA (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis
    • Oct 10, 2014: Oral OTEZLA (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis
    • Oct 08, 2014: Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis
    • Oct 01, 2014: Novartis showcases dermatology leadership on International Urticaria Day announcing new data to be presented at EADV 2014
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • The LEO Foundation
      • Clinical Trial Overview of The LEO Foundation
      • Johnson & Johnson
      • Clinical Trial Overview of Johnson & Johnson
      • Amgen Inc.
      • Clinical Trial Overview of Amgen Inc.
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • AbbVie Inc.
      • Clinical Trial Overview of AbbVie Inc.
      • Maruho Co., Ltd.
      • Clinical Trial Overview of Maruho Co., Ltd.
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • Galderma S.A.
      • Clinical Trial Overview of Galderma S.A.
      • Merck & Co., Inc.
      • Clinical Trial Overview of Merck & Co., Inc.
      • Astellas Pharma Inc.
      • Clinical Trial Overview of Astellas Pharma Inc.
    • Clinical Trial Overview of Top Institutes / Government
      • Guangdong Provincial Hospital of Traditional Chinese Medicine
      • Clinical Trial Overview of Guangdong Provincial Hospital of Traditional Chinese Medicine
      • University of California, San Francisco
      • Clinical Trial Overview of University of California, San Francisco
      • Mount Sinai Hospital
      • Clinical Trial Overview of Mount Sinai Hospital
      • Medical University of Vienna
      • Clinical Trial Overview of Medical University of Vienna
      • Rockefeller University
      • Clinical Trial Overview of Rockefeller University
      • Dresden University of Technology
      • Clinical Trial Overview of Dresden University of Technology
      • Tehran University of Medical Sciences
      • Clinical Trial Overview of Tehran University of Medical Sciences
      • Peking University People's Hospital
      • Clinical Trial Overview of Peking University People's Hospital
      • Chang Gung Memorial Foundation
      • Clinical Trial Overview of Chang Gung Memorial Foundation
      • Postgraduate Institute of Medical Education and Research
      • Clinical Trial Overview of Postgraduate Institute of Medical Education and Research
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Region, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014*
  • Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials, G7 Countries (%), 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials, E7 Countries (%), 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by The LEO Foundation, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Maruho Co., Ltd., 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Galderma S.A., 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Guangdong Provincial Hospital of Traditional Chinese Medicine, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Mount Sinai Hospital, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Rockefeller University, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Dresden University of Technology, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Peking University People's Hospital, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Chang Gung Memorial Foundation, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Postgraduate Institute of Medical Education and Research, 2014*

List of Figures

  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014*
  • Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials, G7 Countries (%), 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials, E7 Countries (%), 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top